Phase 2 N=77 A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381
Coronary Heart Disease
Primary: Percent Change From Baseline in HDL-C — 33.76; 3.69 Percentage Change of HDL-C
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=253 A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
Lung Diseases, Interstitial
Primary: Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period — -17.9; 116.6; -90.3; 125.6 milliliter (mL) — p=0.6777
Phase 2 N=130 A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
Coronary Heart Disease
Primary: Percent Change From Baseline in Mean Wall Thickness — 4.245; 6.679 Percent Change
N/A N=20 Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
Ocular Rosacea · Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score — -25.9; -2.0 percentage of change in OSDI score — p=0.0312
N/A N=15 Glucose Measurement Using Microneedle Patches
Diabetes
Primary: Glucose Level — 137; 174.5; 160.9; 155 mg/dL
N/A N=18 Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Overactive Bladder
Primary: Change in Urge Incontinence Episodes — 3.9 UUI
Phase 3 N=820 Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Acne
Primary: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 — -17.8; -10.6 lesion count — p=<0.001
Phase 4 N=190,238 Mortality Reduction After Oral Azithromycin: Mortality Study
Childhood Mortality
Primary: All-cause Mortality Rate in Children Aged 1-60 Months — 14.6; 16.5 deaths per 1000 person-years
N/A N=148 Improving Communication Between Cancer Patients & Oncologists
Cancer
Primary: Provider to Patient Communication Score — 1.0423; 1.0723 score on a scale
Phase 3 N=702 Treatment for CI-DME in Eyes With Very Good VA Study
Diabetic Macular Edema
Primary: Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline — 33; 36; 39 Eyes
Phase 3 N=15,871 A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
Coronary Heart Disease
Primary: Incidence of Cardiovascular Mortality and Morbidity — 0.034050; 0.032759 Event per Patient Years of Followup
Phase 2 N=50 Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1
HIV Infections
Primary: Mean Logarithm With Base 10 (Log10) Change From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Day 9 — -1.3445; -1.2532; -1.2381; -1.1888 Log10…
N/A N=155 Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus
Infections, Cytomegalovirus · Cytomegalovirus Infections
Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants
N/A N=68 Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)
CCR5-tropic HIV-1 Infection
Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 23.53 percentage of participants
Phase 2 N=476 A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
Coronary Heart Disease
Primary: Change From Baseline in % Flow Mediated Dilatation (FMD) — 0.09; 0.32 %FMD